In veterinary oncology, research is increasingly focused on developing canine-specific antibodies, with anti-PD-1 and anti-PD-L1 therapies showing significant potential, mirroring the progress made in human cancer treatment (Figure 5) [54,55]. Here, CD274 is linked to cancer.